早期治疗优化不足对难治性类风湿关节炎的早期特征描述:一项多中心队列研究
这项回顾性多中心队列研究纳入48例难治性类风湿关节炎(D2T-RA)患者和145例非D2T-RA对照,发现甲氨蝶呤未在3个月内启动(OR 0.3;95%CI 0.1,0.9)和糖皮质激素6个月后未停用(OR 4.6;95%CI 2.2,9.5)与D2T-RA显著相关。结论认为甲氨蝶呤未在3个月内启动及糖皮质激素未在6个月内停用是D2T-RA的早期预测特征。
要点
- D2T-RA患者中甲氨蝶呤3个月内启动者占16.7%,非D2T-RA为33.1%(P=0.011)。
- D2T-RA患者中糖皮质激素6个月后仍继续使用者占70.8%,非D2T-RA为33.8%(P<0.001)。
- 甲氨蝶呤未在3个月内启动和糖皮质激素6个月后未停用与D2T-RA显著相关。
核心结论
- 甲氨蝶呤未在3个月内启动和糖皮质激素未在6个月内停用是D2T-RA的早期预测特征。
研究设计与样本
- 回顾性多中心队列研究,纳入符合2010年ACR/EULAR类风湿关节炎诊断标准、2000至2019年确诊的个体,研究时间为2021年9月至2022年3月。
- 共纳入48例D2T-RA患者和145例非D2T-RA对照,结局为按EULAR定义的D2T-RA。
- 采用稳健回归分析与甲氨蝶呤延迟、剂量、持续时间及糖皮质激素停用的关联,并用多项回归检验与持续性炎症难治性RA(PIRRA)或非炎症性难治性RA(NIRRA)相关的因素。
- 敏感性分析包括按诊断年份匹配的病例对照研究。
主要发现
- 甲氨蝶呤在3个月内启动者中D2T-RA占16.7%,非D2T-RA占33.1%(P=0.011)。
- 甲氨蝶呤获得足够持续时间者在D2T-RA患者中显著更少(70.8% vs 85.5%)。
- 糖皮质激素在6个月后仍继续使用者在D2T-RA患者中比例更高(70.8% vs 33.8%,P<0.001)。
- 多因素回归中,治疗延迟超过3个月与D2T-RA显著相关(OR 0.3;95%CI 0.1,0.9)。
- 多因素回归中,糖皮质激素6个月后未停用与D2T-RA显著相关(OR 4.6;95%CI 2.2,9.5)。
关键数值与推荐
- 甲氨蝶呤在3个月内启动者:D2T-RA组16.7% vs 非D2T-RA组33.1%(P=0.011)。
- 甲氨蝶呤足够持续时间:D2T-RA组70.8% vs 非D2T-RA组85.5%。
- 糖皮质激素6个月后继续使用:D2T-RA组70.8% vs 非D2T-RA组33.8%(P<0.001)。
- 治疗延迟超过3个月与D2T-RA的OR为0.3(95%CI 0.1,0.9)。
- 糖皮质激素6个月后未停用与D2T-RA的OR为4.6(95%CI 2.2,9.5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To demonstrate that unsuccessful treatment optimization in early disease is associated with difficult-to-treat RA (D2T-RA). METHODS: In this retrospective multicentre cohort study conducted from 09/2021-03/2022, we enrolled individuals fulfilling the 2010 ACR/EULAR RA criteria diagnosed 2000-2019. The outcome was D2T-RA by the EULAR definition. We used robust regression to examine the associations with delay, dose, duration of methotrexate and discontinuation of glucocorticoids. We tested through multinomial regression which factors were associated with persistent inflammatory refractory RA (PIRRA) or non-inflammatory refractory RA (NIRRA). Sensitivity analysis included a case-control study matching the year of diagnosis. RESULTS: We enrolled 48 D2T-RA patients and 145 non-D2T-RA controls. Methotrexate was started within 3 months in 16.7% of D2T-RA vs 33.1% of non-D2T-RA (P = 0.011). Adequate duration of methotrexate was obtained in significantly fewer D2T-RA patients (70.8% vs 85.5%). Glucocorticoids were continued beyond 6 months in a higher proportion of D2T-RA patients (70.8% vs 33.8%, P < 0.001). In multiple regression, treatment delay beyond 3 months (OR 0.3; 95% CI 0.1, 0.9) and non-discontinuation of glucocorticoids after 6 months (OR 4.6; 95% CI 2.2, 9.5) were significantly associated with D2T-RA. Treatment delay was significantly associated with PIRRA only, while non-discontinuation of glucocorticoids was significantly associated with PIRRA and NIRRA. Results were replicated in sensitivity analyses. CONCLUSION: Failure to start methotrexate within 3 months and not being off glucocorticoids within 6 months are early predictive features of D2T-RA.
引用
- Giollo A, Zen M, Larosa M, et al. Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study. Rheumatology (Oxford). 2023. PMID: 36190344. doi:10.1093/rheumatology/keac563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。